Maxigen Biotech (TPE:1783) Margin of Safety % (DCF Earnings Based): N/A (As of Jun. 26, 2026)


TPE:1783 Maxigen Biotech Inc TPE:1783
87 GF Score
Price NT$38.10
GF Value NT$60.99
Valuation Significantly Undervalued
View Full Analysis

What is Maxigen Biotech Margin of Safety % (DCF Earnings Based)?

Margin of Safety % (DCF Earnings Based) = (Intrinsic Value: DCF (Earnings Based) - Current Price) / Intrinsic Value: DCF (Earnings Based).

Note: Discounted Earnings model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

Maxigen Biotech's Predictability Rank is 1-Star. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF Earnings Based) is not calculated.

TPE:1783 vs ISRG, BDX, MDLN: Margin of Safety % (DCF Earnings Based) Comparison

For the Medical Instruments & Supplies subindustry, Maxigen Biotech's Margin of Safety % (DCF Earnings Based), along with its competitors' market caps and Margin of Safety % (DCF Earnings Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Maxigen Biotech Margin of Safety % (DCF Earnings Based) vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Maxigen Biotech's Margin of Safety % (DCF Earnings Based) distribution charts can be found below:

* The bar in red indicates where Maxigen Biotech's Margin of Safety % (DCF Earnings Based) falls into.


TPE:1783
87GF Score
Maxigen Biotech Inc TPE:1783
Margin of Safety % (DCF Earnings Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Maxigen Biotech (TPE:1783) Overvalued in 2026?

Based on GuruFocus' analysis, Maxigen Biotech stock appears to be undervalued. The current stock price of NT$38.10 is trading 37.5% below its estimated GF Value™ of NT$60.99. GuruFocus considers Maxigen Biotech to be Significantly Undervalued.

Key valuation signals for TPE:1783:

  • Margin of Safety % (DCF Earnings Based): N/A
  • GF Value™: NT$60.99 vs. price of NT$38.10 (37.5% below fair value)
  • GF Score™: 87/100

No single metric tells the full story. See the TPE:1783 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Maxigen Biotech Business Description

Address No.88, Keji 1st Road, Guishan District, Taoyuan City, TWN, 333
Maxigen Biotech Inc is engaged in collagen purification, research and development, production and sales of implantable medical device, and production, manufacturing, wholesale and retail of cosmetics. The group had two reportable segments: the biomedical products segment and consumer products segment. Biomedical products segment is engaged in the manufacturing and sales of collagen and bone materials. The consumer products segment is involved in the manufacturing and sales of beauty care products. Geographically, it operates in Taiwan, America, Europe, Asia, and other countries, with the majority of the revenue deriving from Taiwan.
87GF Score

Get the complete analysis for TPE:1783

Margin of Safety % (DCF Earnings Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$38.10
Price
NT$60.99
GF Value